Skip to main content

Clinical Trials Using Letrozole

Review the clinical trials studying letrozole on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-47 of 47

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Status: Active
Location: 4 locations
Abemaciclib and Letrozole with Radiation Prior to Surgery for the Treatment of HR-Positive, HER2-Negative Invasive Breast Cancer, RADIANT Trial
Status: Active
Location: 4 locations
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Status: Active
Location: 4 locations
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: Active
Location: 3 locations
Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Status: Active
Location: 3 locations
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 3 locations
Neoadjuvant Letrozole with or without Abemaciclib in Hormone Receptor Positive Breast Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Status: Active
Location: 2 locations
Medication Switch versus Guideline-directed Intervention (Side Effect Management) in Reducing Side Effects of Aromatase Inhibitors in Estrogen Receptor Positive HER2 Negative Breast Ductal Carcinoma In Situ and Stage I-III Invasive Breast Cancer, SWIVEL Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Zanidatamab before Surgery for the Treatment of Early Stage HER2/Neu Positive Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Status: Active
Location: UPMC Hillman Cancer Center Erie, Erie, Pennsylvania
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Status: Active
Location: See ClinicalTrials.gov
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
Status: Temporarily Closed to Accrual
Location: 704 locations
Ovarian Simulation and Tamoxifen or Letrozole in Fertility Preservation in Patients with Breast Cancer, TALES Study
Status: Active
Location: 2 locations